BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, December 9, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

May 19, 2000

View Archived Issues

Zambon and Sheffield file for MSI-Albuterol approval via European centralized procedure

Read More

Novel therapeutic approaches for diabetic nephropathy explored

Read More

Incara advances research programs during first four months of the year

Read More

RxKinetix and Elan form joint venture for oral mucositis drug development

Read More

Interneuron highlights Q2 developments

Read More

Ciblex's CBX-10913 blocks inflammation in mice

Read More

Exelon gains Canadian approval as new treatment for Alzheimer's disease

Read More

Yale receives NIDA grant to advance Cantab's anticocaine vaccine

Read More

CV Therapeutics moves CVT-510 to phase III

Read More

EntreMed responds to premature disclosure of trial data

Read More

New inhibitor of ICAM-1/LFA-1-mediated cell adhesion produced by Streptomyces

Read More

Squalamine demonstrates preclinical activity in retinopathy

Read More

SuperGen anticancer compound subject of new CRADA

Read More

Pantoprazole now available for more uses

Read More

Lilly's Evista receives additional approval in E.U. for the treatment of osteoporosis

Read More

Pierre Fabre becomes Recordati's partner for lercanidipine in France

Read More

New treatment option for patients with atrial fibrillation/atrial flutter introduced in U.S.

Read More

First market launch for novel antiepileptic drug Keppra

Read More

Leflunomide analogue protects against renal allograft rejection in combination with ciclosporin

Read More

Cognetix and collaborators discover novel conopeptides interacting with voltage-gated K+ channels

Read More

Selective RXR agonists designed at Allergan particularly useful for skin-related diseases

Read More

Two new series of PDE5 inhibitors claimed by Pfizer

Read More

Imidazolones targeting Y5 receptors described by BMS as anorectic agents

Read More

Antisense oligonucleotides for modifying bcl-x expression in the Isis pipeline

Read More

Abbott continues to search for new ketolide antibacterial agents

Read More

FDA denies approval for Refludan in acute coronary syndrome

Read More

Major approval obtained for Mylotarg, the first antibody-targeted chemotherapy product

Read More

Clinical data support equivalence of Gengraf and Neoral; Gengraf approved by FDA

Read More

Transplant 2000 news: novel strategy for preventing chronic rejection in renal allograft recipients

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 8, 2025.
  • Mesothelin is biomarker, potential target in arthritic bone damage

    BioWorld Science
    In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing